serum
plasma
proteas
associ
variou
diseas
includ
cancer
inflamm
renocardiovascular
diseas
aim
investig
whether
enzymat
activ
serum
proteas
associ
estim
glomerular
filtrat
rate
egfr
patient
differ
stage
chronic
kidney
diseas
ckd
studi
popul
compris
particip
greifswald
approach
individu
medicin
ganim
cohort
enzymat
activ
aminopeptidas
aminopeptidas
b
alanyl
membran
aminopeptidas
insulinregul
aminopeptidas
puromycinsensit
aminopeptidas
leucin
aminopeptidas
prolylendopeptidas
pep
dipeptidyl
peptidas
angiotensin
iconvert
enzym
angiotensin
iconvert
enzym
proteas
measur
serum
linear
regress
respect
proteas
perform
kidney
function
adjust
age
sex
kidney
function
model
either
continu
modif
diet
renal
diseas
mdrd
base
egfr
dichotom
egfr
respect
result
fals
discoveri
rate
deem
statist
signific
among
proteas
investig
activ
correl
egfr
patient
lowest
egfr
exhibit
highest
activ
pep
correl
age
serum
proteas
activ
show
associ
age
sex
data
indic
enzymat
activ
associ
egfr
patient
ckd
find
distinguish
serum
peptidas
analyz
clearli
indic
analys
warrant
identifi
precis
role
serum
ectopeptidas
pathogenesi
ckd
fulli
elucid
underli
molecular
mechan
renal
cardiac
diseas
common
often
occur
concomitantli
result
increas
morbid
mortal
understand
molecular
mechan
link
diseas
limit
avail
fragmentari
data
point
role
reninangiotensin
system
ra
particular
rasrel
peptidas
comprehens
analysi
serum
peptidas
activ
patient
differ
stage
chronic
kidney
diseas
ckd
present
special
emphasi
given
ra
peptidas
serum
activ
peptidas
angiotensin
iconvert
enzym
dipeptidyl
peptidas
identifi
close
associ
kidney
function
specif
estim
glomerular
filtrat
rate
find
discuss
context
avail
data
suggest
protect
role
enzym
renocardiac
diseas
data
add
understand
pathomechan
underli
develop
progress
ckd
indic
enzym
might
repres
potenti
pharmacolog
target
preserv
renal
function
last
decad
membranebound
proteasespeptidas
ectopeptidas
gain
consider
research
interest
due
contribut
format
competit
metabol
degrad
broad
varieti
peptid
hormon
function
key
regul
intercellular
commun
pathophysiolog
condit
particular
cardioren
diseas
greatli
affect
releas
shed
ectopeptidas
extracellular
compart
includ
blood
plasma
member
disintegrin
metalloproteas
famili
prototyp
sheddas
implic
process
solubl
peptidasesproteas
shed
plasma
may
repres
possibl
sourc
biomark
thu
studi
comprehens
analysi
serum
ectopeptidas
activ
patient
chronic
kidney
diseas
ckd
differ
diseas
stage
perform
special
emphasi
given
peptidasesproteas
reninangiotensin
system
ra
dysregul
activ
classic
altern
axe
ra
associ
cardiac
renal
diseas
cardiac
renal
diseas
common
often
occur
concomitantli
result
increas
morbid
mortal
date
world
popul
affect
ckd
next
decad
ckd
preval
increas
due
rise
preval
major
risk
factor
ckd
includ
diabet
hypertens
cardiovascular
disord
increasingli
older
popul
ckd
defin
structur
patholog
kidney
transplant
declin
estim
glomerular
filtrat
rate
egfr
threemonth
time
clinic
implic
albuminuria
experiment
clinic
data
indic
administr
inhibitor
angiotensinconvert
enzym
acei
angiotensin
ii
type
receptor
blocker
limit
progress
kidney
injuri
albuminuria
damag
podocyt
decreas
egfr
due
chronic
volum
overload
angiotensin
ii
angii
promot
product
reactiv
oxygen
speci
renal
fibrosi
via
direct
activ
nadph
oxidas
indirect
increas
aldosteron
plasma
concentr
mechan
accordingli
aldosteron
receptor
antagonist
also
shown
diminish
histolog
sign
kidney
injuri
creatinin
serum
concentr
proteinuria
solvd
studi
enalapril
reduc
proteinuria
diabet
patient
captopril
stabil
gfr
postinfarct
patient
heart
failur
howev
consensu
studi
show
increas
serum
creatinin
patient
treat
enalapril
slight
decreas
gfr
observ
valsartan
valheft
studi
furthermor
candesartan
abl
reduc
proteinuria
charmad
studi
summari
avail
studi
provid
simpl
answer
question
precis
role
ra
particular
differ
axe
develop
progress
ckd
actual
better
understand
might
hamper
extens
heterogen
among
patient
ckd
respect
underli
pathomechan
concomit
diseas
howev
diseas
gender
agedepend
dysregul
typic
ra
proteas
might
partli
compens
modul
expressionact
ectoproteas
support
view
shown
previous
agedepend
decreas
ace
activ
pericardi
fluid
elder
women
compens
increas
activ
membran
alanylaminopeptidas
apn
dipeptidylpeptidas
iv
dppiv
advanc
age
acei
treatment
could
increas
pathophysiolog
relev
nonra
proteas
studi
determin
enzymat
activ
rasrel
ectopeptidas
ace
aminopeptidas
apa
aminopeptidas
b
apb
apn
insulinregul
aminopeptidas
irap
well
puromycinsensit
aminopeptidas
psa
leucin
aminopeptidas
lap
prolylendopeptidas
pep
serum
sampl
patient
differ
stage
ckd
egfr
group
proteas
characterist
summar
tabl
patient
select
greifswald
approach
individu
medicin
ganim
project
ganim
aim
implement
individu
diagnost
therapeut
measur
patient
cohort
common
cardiovascular
cerebrovascular
metabol
condit
pulmonari
diseas
sepsi
patient
advers
medic
effect
ganim
patient
recruit
univers
hospit
special
dialysi
treatment
center
patient
subject
highli
standard
anamnest
somatometr
basic
laboratori
diagnost
analys
also
includ
determin
egfr
cohort
profil
detail
studi
procedur
pleas
refer
grabe
et
al
ganim
approv
ethic
committe
medic
faculti
univers
greifswald
particip
provid
inform
written
consent
present
studi
data
ganim
patient
enrol
juli
decemb
renal
renovascular
diseas
cohort
analyz
none
patient
underw
renal
transplant
inclus
studi
patient
consent
blood
sampl
subsequ
measur
serum
proteas
activ
plasma
creatinin
concentr
perform
patient
assign
differ
ckd
stage
accord
egfr
group
ckd
egfr
group
ckd
egfr
group
ckd
egfr
group
ckd
egfr
group
ckd
egfr
number
patient
ckd
stage
natur
low
renal
cohort
patient
ageand
sexmatch
patient
ganim
cardiovascular
cohort
select
fill
stage
group
compris
patient
blood
sampl
eight
millilit
blood
drawn
cubit
vein
use
needl
becton
dickinson
diagnost
system
usa
sst
ii
advanc
vacutain
becton
dickinson
diagnost
system
usa
tube
serum
sampl
blood
sampl
rest
min
undergo
coagul
follow
centrifug
g
min
supernat
fill
ml
sampl
tube
eppendorf
germani
store
c
analysi
determin
proteas
activ
plasma
creatinin
perform
separ
collect
tube
howev
obtain
one
blood
draw
determin
proteas
activ
enzymat
activ
ace
apa
apb
apn
lap
pep
psa
irap
determin
serum
sampl
one
freezethaw
cycl
use
substrat
inhibitor
specifi
tabl
assay
determin
apa
apb
apn
lap
pep
psa
irap
enzymat
activ
carri
mm
hepe
buffer
contain
mm
nacl
mm
zncl
dmso
ph
enzym
reaction
perform
flatbottom
microtit
plate
greiner
bioon
frickenhausen
germani
total
reaction
volum
amount
ml
consist
ml
buffer
ml
serum
ml
substrat
reaction
start
addit
substrat
appropri
inhibitor
use
increas
specif
assay
eg
appli
discrimin
apn
sensit
psa
insensit
alapnahydrolyz
activ
well
irap
sensit
lap
insensit
leupnahydrolyz
activ
lysznothiazolidid
use
distinguish
sensit
pep
insensit
inhibitor
appli
preincub
inhibitor
perform
min
c
addit
substrat
optic
densiti
start
point
use
blank
sampl
incub
c
h
dark
optic
densiti
measur
nm
nm
refer
wavelength
microtit
plate
reader
infinit
tecan
crailsheim
germani
enzymat
activ
ace
determin
use
ace
colorkit
mastdiagnosticagmbh
reinfeld
germani
accord
manufactur
instruct
adapt
plate
lisinoprilinsensit
fraction
consid
activ
sampl
analyz
duplic
reanalysi
indic
valu
differ
enzymat
activ
given
nkatl
calcul
follow
vt
vs
l
creatinin
measur
egfr
plasma
creatinin
concentr
ganim
measur
institut
clinic
chemistri
laboratori
medicin
univers
medicin
greifswald
greifswald
germani
ganim
start
creatinin
measur
perform
modifi
kinet
method
siemen
dimens
vista
siemen
healthcar
diagnost
eschborn
germani
novemb
new
enzymat
method
creatinin
measur
siemen
dimens
vista
introduc
lab
subsequ
ganim
sampl
measur
method
method
chang
may
lead
uncompar
valu
method
comparison
perform
comparison
plasma
sampl
mmoll
creatinin
measur
method
comparison
respect
pair
reveal
enzymat
method
measur
lower
creatinin
concentr
differ
base
median
modifi
kinet
method
therefor
consid
necessari
convert
creatinin
concentr
measur
method
newer
enzymat
method
passingbablok
regress
r
yield
coeffici
follow
formula
creatinin
enzymat
mmoll
creatinin
mmoll
formula
appli
convert
measur
obtain
method
enzymat
method
analys
base
convert
data
egfr
calcul
use
fourvari
mdrd
equat
mdrd
formula
chosen
subject
includ
present
studi
egfr
valu
mdrd
formula
high
accuraci
mention
egfr
group
sampl
avail
ckd
cohort
design
sampl
cardiovascular
cohort
select
randomli
match
age
sex
detail
two
sampl
ad
egfr
group
respect
sampl
size
per
group
success
measur
proteas
activ
present
tabl
analys
linear
regress
respect
proteas
activ
kidney
function
adjust
age
year
sex
calcul
kidney
function
model
either
use
continu
egfr
valu
egfrcreamdrd
group
dichotom
egfr
respect
dichotom
calcul
base
group
perform
sensit
analys
address
potenti
nonlinear
relationship
egfr
valu
proteas
activ
result
adjust
multipl
test
appli
fals
discoveri
rate
fdr
claim
signific
fdr
analys
carri
r
wwwrpro
jectorg
total
patient
includ
studi
classif
patient
egfr
group
given
tabl
multivari
regress
analysi
reveal
signific
associ
patient
egfr
serum
enzymat
activ
associ
remain
signific
adjust
age
sex
tabl
proteas
analyz
associ
enzymat
activ
egfr
detect
tabl
categor
analysi
egfr
group
confirm
signific
associ
serum
activ
egfr
group
overal
p
valu
p
p
figur
shown
figur
egfr
group
group
show
lowest
activ
thu
dichotom
analysi
perform
compar
proteas
activ
patient
egfr
patient
egfr
result
show
significantli
higher
activ
patient
egfr
p
supplementari
tabl
egfr
group
exhibit
highest
serum
activ
level
group
figur
b
dichotom
analysi
activ
patient
egfr
versu
confirm
significantli
higher
serum
activ
patient
egfr
compar
patient
higher
egfr
p
supplementari
tabl
note
ace
enpep
npepp
pass
signific
threshold
analys
patient
egfr
respect
analysi
pep
invers
correl
age
tabl
wherea
none
other
proteas
studi
show
signific
ageor
sexdepend
chang
serum
activ
supplementari
tabl
among
patient
includ
studi
atrial
fibril
af
medic
histori
agreement
establish
fact
af
preval
increas
age
studi
af
posit
correl
age
r
p
af
correl
proteas
activ
supplementari
tabl
ace
activ
influenc
medic
atc
code
agent
act
ra
howev
signific
associ
egfr
activ
respect
remain
adjust
medic
intak
perform
comprehens
analysi
serum
proteas
activ
assess
potenti
associ
ckd
proteas
activ
studi
found
associ
egfr
fairli
well
character
part
altern
ma
axi
ra
kidney
among
tissu
highest
express
level
polar
kidney
cell
appear
preferenti
express
apic
surfac
proteolyt
cleav
apic
surfac
releas
solubl
form
human
plasma
enzymat
activ
rather
low
depend
assay
appli
clinic
set
might
even
low
measur
nevertheless
plasma
serum
enzymat
activ
exert
signific
protect
effect
due
abil
convert
angii
major
effector
peptid
classic
aceangii
ra
axi
ang
protect
activ
ang
observ
anim
model
xu
et
al
patient
ckd
accordingli
loss
shown
exacerb
experiment
renal
ischemiareperfus
injuri
pharmacolog
inhibit
aggrav
albuminuria
nephrectomi
mice
latter
effect
could
prevent
antagonist
losartan
mutual
influenc
classic
altern
ang
axi
ra
also
emphas
interest
data
reich
et
al
found
mrna
level
reduc
wherea
ace
mrna
level
increas
glomerular
proxim
tubular
cell
diabet
patient
anoth
studi
reveal
differ
renal
express
patient
divers
primari
secondari
renal
diseas
includ
patient
diabet
nephropathi
podocyt
shown
preferenti
express
compon
altern
ra
axi
neprilysin
aminopeptidas
renin
lead
primarili
format
ang
simultan
degrad
angii
patient
cohort
direct
serum
activ
without
remov
endogen
inhibitor
prior
activ
measur
invers
associ
egfr
lowest
activ
found
patient
group
exhibit
egfr
shown
previous
plasma
level
low
healthi
subject
substanti
increas
patholog
condit
includ
cardiac
diseas
diabet
higher
serum
activ
patient
lower
egfr
observ
could
repres
similar
compensatori
protect
mechan
aim
counteract
diseaseassoci
induct
classic
ra
axi
elev
angii
level
associ
previous
variou
cardiovascular
cardioren
risk
factor
includ
diabet
hypertens
obes
hyperlipidemia
recent
studi
howev
robert
et
al
report
lower
plasma
activ
patient
hemodialysi
compar
ckd
patient
requir
hemodialysi
stage
egfr
particularli
true
activ
inhibitor
remov
indirect
activ
decreas
wherea
direct
activ
significantli
affect
lower
latter
find
might
partli
explain
discrep
result
emphas
howev
activ
measur
studi
rang
previous
report
notabl
direct
enzymat
activ
healthi
control
nkatl
wang
et
al
closest
patient
wellpreserv
egfr
studi
nkatl
recent
studi
observ
lower
circul
activ
ckd
activ
nkatl
figur
serum
activ
accord
egfr
group
serum
activ
invers
correl
egfr
patient
wellpreserv
egfr
egfr
group
lower
activ
group
p
b
activ
accord
egfr
group
significantli
higher
serum
activ
observ
patient
egfr
compar
serum
activ
patient
egfr
p
angiotensin
iconvert
enzym
dipeptidylpeptidas
egfr
estim
glomerular
filtrat
rate
patient
without
concomit
cardiovascular
diseas
stage
compar
control
urinari
level
found
increas
diabet
patient
patient
ckd
stage
compar
urinari
seem
reflect
glomerular
damag
associ
albuminuria
urinari
livertyp
fatti
acid
bind
protein
level
dipeptidyl
peptidas
kda
type
ii
membran
protein
plasma
membran
occur
kda
homodimer
peptidas
enzym
ubiquit
express
highest
express
level
kidney
spleen
lung
furthermor
establish
tcell
activ
marker
implic
tcell
function
variou
diseas
particular
cancer
associ
alter
expressionact
bone
marrowderiv
cell
kidney
identifi
sourc
solubl
serum
level
subject
chang
alter
activ
associ
variou
cancer
activ
increas
oral
glucos
load
healthi
subject
postprolin
cleav
substrat
specif
make
rel
uniqu
among
proteas
preferenti
remov
xpro
also
xala
dipeptid
nterminu
substrat
among
establish
substrat
therefor
inhibitor
gliptin
emerg
antidiabet
compound
increas
clinic
use
implic
preserv
renal
function
streptozotocininduc
diabet
rat
nonobes
diabet
mous
latter
insulin
improv
renal
function
well
circul
renal
activ
howev
inhibit
appear
nephroprotect
mechan
independ
chang
blood
glucos
view
support
recent
studi
demonstr
two
differ
anim
model
renal
injuri
dbdb
mice
adriamycininduc
nephropathi
inhibitor
improv
proteinuria
renal
fibrosi
urinari
nephrin
loss
without
affect
glycem
control
similarili
gemigliptin
suppress
albuminuria
reduc
apoptosi
podocyt
independ
glucoselow
effect
furthermor
inhibit
vildagliptin
shown
restor
urinari
flow
gfr
proteinuria
rat
model
heart
failureinduc
renal
dysfunct
recent
data
provid
mechanist
insight
role
demonstr
linagliptin
prevent
receptordepend
manner
model
diabet
nephropathi
furthermor
inhibitor
normal
angiidepend
decreas
express
megalin
endocyt
receptor
proxim
tubul
emphas
import
contribut
inappropri
activ
ra
due
eg
hypertens
af
obes
hyperlipidemia
hyperglycemia
ckd
inhibitor
shown
reduc
fibrot
inflammatori
marker
nfkb
angii
mitogenactiv
kinas
possibl
mediat
identifi
studi
observ
neg
associ
egfr
serum
activ
highest
activ
ae
nkatl
mean
ae
sd
found
patient
egfr
activ
rang
lower
previous
publish
refer
valu
note
previou
work
consid
contribut
member
famili
glypropnahydrolyz
activ
use
measur
serum
plasma
activ
assay
studi
activ
defin
fraction
glypropnahydrolyz
activ
could
inhibit
lysznitrothiazolidid
therebi
exclud
noninhibit
fraction
rather
repres
pep
activ
wherea
durinx
et
al
observ
declin
serum
activ
grow
age
higher
activ
men
women
effect
could
observ
age
appar
discrep
might
due
applic
specif
inhibitor
studi
agedepend
increas
glypropnahydrolyz
activ
observ
previous
pericardi
fluid
elder
femal
patient
year
coronari
arteri
diseas
wherea
elder
male
patient
show
tendenc
toward
decreas
activ
anoth
studi
activ
higher
patient
appropri
implant
cardioverterdefibril
icd
intervent
patient
without
icd
intervent
activ
neg
correl
age
find
suggest
specif
respons
divers
pathophysiolog
condit
may
depend
age
sex
although
ace
enpep
npepp
pass
signific
threshold
one
dichotom
analys
studi
need
test
whether
enzymat
activ
truli
associ
egfr
sinc
associ
close
signific
level
one
specif
dichotom
analysi
test
thu
give
inconclus
result
summari
data
indic
enzymat
activ
enzymat
activ
sever
serum
peptidas
associ
egfr
patient
ckd
remain
establish
extent
alter
proteas
activ
may
serv
use
marker
monitor
develop
progress
ckd
howev
find
clearli
show
analys
warrant
identifi
precis
role
serum
ectopeptidas
pathogenesi
ckd
fulli
elucid
underli
molecular
mechan
author
contribut
author
particip
design
studi
interpret
data
review
manuscript
ah
perform
statist
analys
ah
cw
ul
perform
laboratori
experi
bf
ke
ne
rr
sa
sbf
ss
contribut
datamaterialsanalysi
tool
cw
ul
wrote
manuscript
ah
rr
check
polish
manuscript
author
read
approv
final
manuscript
